Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TCBP

TC BioPharm (Holdings) plc ADR

May 08 • 04:00PM ET

1.24

Dollar change +0.01
Percentage change 0.81	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-44.53	Insider Own	-	Shs Outstand	1.03M	Perf Week	-16.22%
Market Cap	3.97M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-33.33%
Income	-1.80M	PEG	-	EPS next Q	-	Inst Own	2.87%	Short Float	-	Perf Quarter	31.79%
Sales	3.35M	P/S	1.18	EPS this Y	-	Inst Trans	0.25%	Short Ratio	0.04	Perf Half Y	-87.18%
Book/sh	0.01	P/B	96.72	EPS next Y	-	ROA	-13.34%	Short Interest	0.24M	Perf Year	-93.33%
Cash/sh	0.76	P/C	1.63	EPS next 5Y	-	ROE	-94.90%	52W Range	0.85 - 21.20	Perf YTD	-60.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.82%	ROI	-38.53%	52W High	-94.15%	Beta	0.15
Dividend TTM	-	Quick Ratio	1.09	Sales past 5Y	-15.17%	Gross Margin	-	52W Low	45.87%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	1.09	EPS Y/Y TTM	-	Oper. Margin	-416.80%	RSI (14)	39.15	Volatility	38.91% 16.31%
Employees	41	Debt/Eq	1.16	Sales Y/Y TTM	-	Profit Margin	-53.62%	Recom	1.00	Target Price	138.50
Option/Short	No / Yes	LT Debt/Eq	0.83	EPS Q/Q	-	Payout	-	Rel Volume	0.13	Prev Close	1.23
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	2.07%	Earnings	-	Avg Volume	5.33M	Price	1.24
SMA20	-16.35%	SMA50	-16.24%	SMA200	-77.30%	Trades		Volume	687,773	Change	0.81%

May-06-24 01:01PM	TC BioPharm Announces Exercise of Warrants for 3.1 Million Gross Proceeds (PR Newswire)
11:32AM	ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range? (InvestorPlace)
11:07AM	Warren Buffett Just Gave Up on Paramount (PARA) Stock (InvestorPlace)
10:37AM	Why Is TC Biopharm (TCBP) Stock Up 51% Today? (InvestorPlace)
08:30AM	TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies (PR Newswire)
10:37AM	Loading…
Apr-04-24 10:37AM	Why Is TC Biopharm (TCBP) Stock Up 78% Today? (InvestorPlace) +50.00%
08:32AM	TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies (PR Newswire)
Apr-02-24 08:30AM	TCBP Increasing Treatment Capacity with Expanded Manufacturing Process (PR Newswire)
Mar-19-24 08:30AM	TCBP Adjourns General Meeting Until a Later Date (PR Newswire) -9.88%
Mar-18-24 08:30AM	TCBP Announces Exercise of Series D Warrants For Cash (PR Newswire)
Mar-01-24 08:30AM	Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated 'The Big Biz Show' (PR Newswire) +5.56%
Feb-27-24 05:15PM	/C O R R E C T I O N -- TC BioPharm/ (PR Newswire)
Feb-22-24 09:32AM	TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial (PR Newswire) +11.94%
Feb-15-24 08:30AM	TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe (PR Newswire)
Feb-14-24 08:30AM	TCBP Provides Shareholder Update and Highlights Upcoming Milestones (PR Newswire) -14.05%
08:30AM	Loading…
Jan-29-24 08:30AM	TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show' (PR Newswire) -13.38%
Jan-18-24 08:30AM	TC BioPharm to Present at the Sequire Investor Summit (PR Newswire)
Jan-04-24 08:30AM	TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire)
Jan-03-24 08:30AM	TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies (PR Newswire) -26.20%
Dec-22-23 08:30AM	TC BioPharm Announces Closing of $3.5 Million Public Offering (PR Newswire)
Dec-19-23 08:00AM	TC BioPharm Announces Pricing of $3.5 Million Public Offering (PR Newswire) -12.87%
Dec-18-23 11:15AM	TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D (PR Newswire)
Dec-13-23 06:30AM	TC BioPharm Announces Plan to Implement ADS Ratio Change (PR Newswire)
Nov-28-23 11:05AM	TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug (Zacks) -7.62%
Nov-27-23 08:45AM	TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia (PR Newswire) -25.52%
Nov-14-23 10:00AM	TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results (PR Newswire) +11.71%
Nov-02-23 01:30PM	TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials (PR Newswire)
Oct-25-23 08:00AM	TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements (PR Newswire)
Oct-24-23 08:45AM	Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments (PR Newswire) -6.88%
Oct-23-23 08:00AM	TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML (PR Newswire) +9.94%
08:00AM	Loading…
Sep-27-23 08:00AM	TC BioPharm to Present at the LD Micro Main Event XVI (PR Newswire)
Sep-05-23 08:30AM	TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL) (PR Newswire)
Aug-29-23 08:30AM	TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Jul-31-23 08:30AM	TC BioPharm Maintains Nasdaq Listing (PR Newswire) +12.81%
Jul-06-23 09:08AM	TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast (Newsfile) -6.42%
May-24-23 09:00AM	TC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023 (PR Newswire)
May-04-23 06:29AM	TC Biopharm (Holdings) Full Year 2022 Earnings: Beats Expectations (Simply Wall St.) -8.11%
Apr-26-23 08:30AM	TC BioPharm Increases Allogeneic Car and Partnering Focus for Advancement of TCB-008 (PR Newswire) -10.14%
Apr-19-23 08:00AM	TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Mar-30-23 04:15PM	TC BioPharm Announces Closing of $5.5 Million Public Offering (PR Newswire)
Mar-28-23 08:05AM	TC BioPharm Announces Pricing of $5.5 Million Public Offering (PR Newswire) -11.68%
Mar-22-23 08:30AM	TC Biopharm Announces Corporate Restructuring, Reduction in Overhead (PR Newswire)
Mar-16-23 12:00PM	TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2) (PR Newswire) +8.40%
Mar-07-23 08:30AM	TC BioPharm Shifts Focus to FDA Clinical Trials (PR Newswire) -9.74%
Feb-23-23 08:30AM	TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer (PR Newswire) -11.13%
Feb-21-23 08:30AM	TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell Therapies (PR Newswire) -32.62%
Feb-14-23 08:30AM	TC BioPharm Announces New Chair of the Board, Arlene Morris (PR Newswire) +14.93%
Feb-13-23 04:15PM	TC BioPharm to Reschedule Shareholder Update Call and Webcast (PR Newswire) +6.68%
Feb-07-23 08:30AM	TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort (PR Newswire)
Jan-30-23 08:30AM	TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division (PR Newswire)
Jan-20-23 08:30AM	TC BioPharm to Host Shareholder Update Call (PR Newswire) -11.73%
Jan-19-23 08:30AM	TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1) (PR Newswire) -17.46%
Jan-17-23 08:30AM	TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology (PR Newswire) +10.04%
Jan-12-23 06:50AM	Daily Vickers Top Buyers & Sellers for 01/12/2023 (Argus Research) +11.50%
Dec-12-22 09:00AM	TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update (PR Newswire)
Nov-30-22 06:43PM	TC BioPharm Announces Closing of $7.35 Million Private Placement (PR Newswire)
Nov-28-22 08:00AM	TC BioPharm Announces $7.35 Million Private Placement (PR Newswire) -31.91%
Nov-22-22 08:00AM	TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia (PR Newswire)
Nov-21-22 05:55AM	TC Biopharm (Holdings) Plc's (NASDAQ:TCBP) biggest owners are individual investors who got richer after stock soared 11% last week (Simply Wall St.) -18.63%
Oct-26-22 08:30AM	TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy Expertise (PR Newswire)
Oct-03-22 08:30AM	TC BioPharm to Present at Upcoming Investor Conferences (PR Newswire)
Sep-13-22 09:30AM	TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune® (PR Newswire)
Aug-22-22 08:30AM	TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Jul-25-22 08:30AM	TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit (PR Newswire)
Jul-08-22 08:30AM	TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" (PR Newswire)
Jun-07-22 04:00PM	TC Biopharm Announces Closing of $4 Million Underwritten Public Offering (PR Newswire)
Jun-02-22 06:10PM	TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering (PR Newswire) -8.90%
May-31-22 10:00AM	TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally (PR Newswire) -8.41%
May-23-22 08:30AM	Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market (PR Newswire) +5.36%
May-18-22 08:30AM	TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts (PR Newswire) +13.41%
May-03-22 08:30AM	TC BioPharm Invited to Present at LD Micro Conference (PR Newswire)
Apr-26-22 08:45AM	TC BioPharm to Participate in Upcoming Conferences (PR Newswire)
Apr-21-22 08:00AM	TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML Day (PR Newswire) -8.21%
Apr-06-22 10:03AM	TC BioPharm Secures CryoTC Trademark For Cell Freezing Process (Benzinga) +7.74%
08:30AM	TC BioPharm Receives CryoTC® Trademark for Proprietary Cell Freezing Process (PR Newswire)
Mar-29-22 08:30AM	TC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" Recommendation (PR Newswire) +8.50%
Mar-23-22 08:30AM	TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Treatment of Acute Myeloid Leukemia (PR Newswire) +10.84%
Mar-17-22 08:30AM	TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune® (PR Newswire) +45.01%
Mar-15-22 08:30AM	TC Biopharm Updates Intellectual Property Portfolio (PR Newswire)
Mar-08-22 08:30AM	TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells (PR Newswire)
Mar-02-22 08:30AM	TC Biopharm to Host Corporate Update Call on March 8th (PR Newswire) +15.71%
Feb-22-22 08:30AM	TC Biopharm Announces Appointment of New Board Members (PR Newswire) -15.38%
Feb-15-22 05:08PM	TC Biopharm Announces Closing of $17.5 Million Initial Public Offering (PR Newswire) -14.78%
Feb-11-22 09:31AM	TC BioPharm Begins Trading on Nasdaq Today Under Symbol "TCBP" (PR Newswire)
Feb-10-22 10:01PM	TC Biopharm Announces Pricing of Upsized $17.5 Million Initial Public Offering and Nasdaq Listing (PR Newswire)

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCBP

TC BioPharm (Holdings) plc ADR

Upgrade your FINVIZ experience